强生公司第三季度销售额超出预期

2020-10-14 15:31

Johnson & Johnson third-quarter sales beat expectations 9WN世界播

强生公司第三季度销售额超出预期9WN世界播


暂无9WN世界播

FDA pledges Covid-19 vaccine will be guided by science 9WN世界播

美国食品药品监督管理局承诺新冠肺炎疫苗将以科学为指导9WN世界播


New York (CNN Business)Johnson & Johnson reported surprisingly strong global sales for the third quarter despite Covid-19-related headwinds. 9WN世界播

纽约(美国有线电视新闻网商业)强生公司公布第三季度全球销售额出人意料地强劲,尽管存在与新冠肺炎相关的逆风。9WN世界播


The company's quarterly sales of $21.1 billion were 1.7% greater than in the same period last year, largely driven by demand for over-the-counter medicines such as Tylenol, said Christopher DelOrefice, J&J's vice president of investor relations. 9WN世界播

强生负责投资者关系的副总裁Christopher DelOrefice称,该公司季度销售额为211亿美元,较上年同期增长1.7%,主要受泰诺等非处方药需求推动。9WN世界播


"E-commerce sales continue to drive growth across most brands," DelOrefice said during an earnings call. Growth was also helped by retailers stocking up ahead of cold and flu season, he said. 9WN世界播

DelOrefice在财报电话会议上表示:“电子商务销售继续推动大多数品牌的增长。”他说,增长也得益于零售商在感冒和流感季节之前囤积库存。9WN世界播


Medical device sales also rose in during the quarter because of a surge in rescheduled treatments that were delayed by the coronavirus pandemic in the spring. 9WN世界播

医疗器械的销售额在本季度也有所上升,因为春季冠状病毒大流行推迟的重新安排的治疗激增。9WN世界播


The better-than-expected earnings came a day after J&J (JENHX) announced it was pausing its Covid-19 vaccine trial following the unexplained illness of a trial volunteer. Executives on Tuesday's earnings call offered few details on the trial. 9WN世界播

在强生宣布暂停新冠肺炎疫苗试验的前一天,该公司公布了好于预期的收益,原因是一名试验志愿者患有不明原因的疾病。在周二的财报电话会议上,高管们几乎没有提供有关审判的细节。9WN世界播


"We know very little information right now," said Mathai Mammen, global head of research and development for Johnson & Johnson's Janssen Pharmaceutical Companies. 9WN世界播

强生旗下扬森制药公司的全球研发主管Mathai Mammen说:“我们现在知道的信息很少。”9WN世界播


Mammen confirmed Johnson & Johnson's leaders were informed of its trial subject's "unexpected illness" Sunday evening, saying the leaders immediately informed the company's ENSEMBLE independent Data and Safety Monitoring Board before posting a statement about the matter on J&J's website on Monday. 9WN世界播

Mammen证实,强生的领导人周日晚上被告知其试验对象的“意想不到的疾病”,称领导人立即通知了该公司的整体独立数据和安全监测委员会,然后于周一在强生的网站上发布了一份关于此事的声明。9WN世界播


"We're now awaiting further medical information and evaluation, which we will then forward to the DSMB for their independent recommendation," Mammen said during the call. "They've asked a number of specific questions. ... It'll be a few days at minimum for the right set of information to be gathered." 9WN世界播

Mammen在电话会议中说:“我们现在正在等待进一步的医疗信息和评估,然后我们将把这些信息转发给DSMB,供他们独立推荐。”“他们问了很多具体的问题……收集正确的信息至少还需要几天时间。”9WN世界播


J&J shares finished down 2.3% on Tuesday. 9WN世界播

强生股价周二收盘下跌2.3%。9WN世界播


Joseph J. Wolk, the company's chief financial officer, sought to quell any concerns that this week's setback implied the company is being urged to rush its development process along with other drugmakers in the ongoing race for a working Covid-19 vaccine. 9WN世界播

该公司首席财务官约瑟夫·J·沃尔克(Joseph J.Wolk)试图平息任何担忧,即本周的挫折意味着,在正在进行的新冠肺炎有效疫苗的竞争中,该公司正被敦促与其他制药商一起加快开发进程。9WN世界播


"We have not encountered any undue pressure and we will maintain the rigorous requirements of research, development and manufacturing to bring a safe and effective Covid-19 vaccine to the public as we do for all our products," he said. 9WN世界播

他说:“我们没有遇到任何不必要的压力,我们将保持研发和制造的严格要求,像我们所有的产品一样,为公众带来安全有效的新冠肺炎疫苗。”9WN世界播

© 2016 世界播 www.shijiebobao.com 中国互联网举报中心 京ICP证140141号 鄂ICP备18018000号-1
违法和不良信息举报: